Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Identifieur interne : 000063 ( an2020/Analysis ); précédent : 000062; suivant : 000064Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Auteurs : Yuan Zhuang [République populaire de Chine] ; Chang Liu [République populaire de Chine] ; Jiaqing Liu [République populaire de Chine] ; Guang Li [République populaire de Chine]Source :
- OncoTargets and therapy [ 1178-6930 ] ; 2020.
Abstract
In recent years, the PD-1/PD-L1 axis blockade has become a very promising therapy with significant clinical benefits for multiple tumor types. However, some patients still do not respond sufficiently to PD-1/PD-L1 targeted monotherapy. Therefore, investigating the mechanism of PD-1 blockade resistance will assist in exploring new immunotherapy strategies, controlling the progress of the disease, and thus bringing more sustainable survival benefits to patients. The tumor-immune cycle is divided into the following seven steps: the release of cancer antigens, cancer antigen presentation, priming and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells. Given that PD-1/PD-L1 blockade is primarily involved in step 7, any abnormalities in the previous steps may affect the efficacy of PD-1/PD-L1 inhibitors and lead to drug resistance. This review discussed the resistance mechanisms of PD-1/PD-L1 blockade in each cancer-immunity step to finding a more suitable treatment population and an optimized combination therapy to exert immunotherapy in tumor treatment to a greater extent.
Url:
DOI: 10.2147/OTT.S239398
PubMed: 32021257
PubMed Central: 6954840
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000A84
- to stream Pmc, to step Curation: 000A84
- to stream Pmc, to step Checkpoint: 000058
- to stream Ncbi, to step Merge: 000E88
- to stream Ncbi, to step Curation: 000E88
- to stream Ncbi, to step Checkpoint: 000E88
- to stream Main, to step Merge: 000063
- to stream Main, to step Curation: 000063
- to stream Main, to step Exploration: 000063
- to stream an2020, to step Extraction: 000063
Links to Exploration step
PMC:6954840Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</title><author><name sortKey="Zhuang, Yuan" sort="Zhuang, Yuan" uniqKey="Zhuang Y" first="Yuan" last="Zhuang">Yuan Zhuang</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Chang" sort="Liu, Chang" uniqKey="Liu C" first="Chang" last="Liu">Chang Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Jiaqing" sort="Liu, Jiaqing" uniqKey="Liu J" first="Jiaqing" last="Liu">Jiaqing Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Li, Guang" sort="Li, Guang" uniqKey="Li G" first="Guang" last="Li">Guang Li</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32021257</idno><idno type="pmc">6954840</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954840</idno><idno type="RBID">PMC:6954840</idno><idno type="doi">10.2147/OTT.S239398</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000A84</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A84</idno><idno type="wicri:Area/Pmc/Curation">000A84</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000A84</idno><idno type="wicri:Area/Pmc/Checkpoint">000058</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000058</idno><idno type="wicri:Area/Ncbi/Merge">000E88</idno><idno type="wicri:Area/Ncbi/Curation">000E88</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E88</idno><idno type="wicri:Area/Main/Merge">000063</idno><idno type="wicri:Area/Main/Curation">000063</idno><idno type="wicri:Area/Main/Exploration">000063</idno><idno type="wicri:Area/an2020/Extraction">000063</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</title><author><name sortKey="Zhuang, Yuan" sort="Zhuang, Yuan" uniqKey="Zhuang Y" first="Yuan" last="Zhuang">Yuan Zhuang</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Chang" sort="Liu, Chang" uniqKey="Liu C" first="Chang" last="Liu">Chang Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Jiaqing" sort="Liu, Jiaqing" uniqKey="Liu J" first="Jiaqing" last="Liu">Jiaqing Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Li, Guang" sort="Li, Guang" uniqKey="Li G" first="Guang" last="Li">Guang Li</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">OncoTargets and therapy</title><idno type="eISSN">1178-6930</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>In recent years, the PD-1/PD-L1 axis blockade has become a very promising therapy with significant clinical benefits for multiple tumor types. However, some patients still do not respond sufficiently to PD-1/PD-L1 targeted monotherapy. Therefore, investigating the mechanism of PD-1 blockade resistance will assist in exploring new immunotherapy strategies, controlling the progress of the disease, and thus bringing more sustainable survival benefits to patients. The tumor-immune cycle is divided into the following seven steps: the release of cancer antigens, cancer antigen presentation, priming and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells. Given that PD-1/PD-L1 blockade is primarily involved in step 7, any abnormalities in the previous steps may affect the efficacy of PD-1/PD-L1 inhibitors and lead to drug resistance. This review discussed the resistance mechanisms of PD-1/PD-L1 blockade in each cancer-immunity step to finding a more suitable treatment population and an optimized combination therapy to exert immunotherapy in tumor treatment to a greater extent.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Zhuang, Yuan" sort="Zhuang, Yuan" uniqKey="Zhuang Y" first="Yuan" last="Zhuang">Yuan Zhuang</name></noRegion><name sortKey="Li, Guang" sort="Li, Guang" uniqKey="Li G" first="Guang" last="Li">Guang Li</name><name sortKey="Liu, Chang" sort="Liu, Chang" uniqKey="Liu C" first="Chang" last="Liu">Chang Liu</name><name sortKey="Liu, Jiaqing" sort="Liu, Jiaqing" uniqKey="Liu J" first="Jiaqing" last="Liu">Jiaqing Liu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/an2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000063 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd -nk 000063 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= an2020
|étape= Analysis
|type= RBID
|clé= PMC:6954840
|texte= Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/an2020/Analysis/RBID.i -Sk "pubmed:32021257" \
| HfdSelect -Kh $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |